Hutchison China Meditech Limited (HCM)

$21.01

+1.06

(+5.31%)▲

Market is closed - opens 7 PM, 07 Oct 2024

Performance

  • $20.52
    $21.14
    $21.01
    downward going graph

    2.33%

    Downside

    Day's Volatility :2.93%

    Upside

    0.61%

    downward going graph
  • $11.93
    $21.92
    $21.01
    downward going graph

    43.2%

    Downside

    52 Weeks Volatility :45.56%

    Upside

    4.15%

    downward going graph

Returns

PeriodHutchison China Meditech LimitedSector (Health Care)Index (Russel 2000)
3 Months
19.46%
4.9%
0.0%
6 Months
18.26%
5.8%
0.0%
1 Year
18.96%
16.5%
0.0%
3 Years
-39.91%
20.3%
-20.1%

Highlights

Market Capitalization
3.6B
Book Value
$0.87
Earnings Per Share (EPS)
-0.25
PEG Ratio
0.0
Wall Street Target Price
28.46
Profit Margin
-6.87%
Operating Margin TTM
-9.0%
Return On Assets TTM
-5.9%
Return On Equity TTM
-5.44%
Revenue TTM
610.8M
Revenue Per Share TTM
3.58
Quarterly Revenue Growth YOY
-42.6%
Gross Profit TTM
-271.6M
EBITDA
-110.2M
Diluted Eps TTM
-0.25
Quarterly Earnings Growth YOY
-0.84
EPS Estimate Current Year
-0.31
EPS Estimate Next Year
0.13
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 22 Wall street analysts offering stock ratings for Hutchison China Meditech Limited(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
20
19
10
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 35.46%

Current $21.01
Target $28.46

Company Financials

FY18Y/Y Change
Revenue
214.1M
↓ 11.23%
Net Income
-74.8M
↑ 179.78%
Net Profit Margin
-34.94%
↓ 23.86%
FY19Y/Y Change
Revenue
204.9M
↓ 4.31%
Net Income
-144.4M
↑ 93.01%
Net Profit Margin
-70.47%
↓ 35.53%
FY20Y/Y Change
Revenue
228.0M
↑ 11.27%
Net Income
-194.6M
↑ 34.76%
Net Profit Margin
-85.34%
↓ 14.87%
FY21Y/Y Change
Revenue
356.1M
↑ 56.21%
Net Income
-227.7M
↑ 17.01%
Net Profit Margin
-63.93%
↑ 21.41%
FY22Y/Y Change
Revenue
426.4M
↑ 19.73%
Net Income
-410.1M
↑ 80.16%
Net Profit Margin
-96.18%
↓ 32.25%
FY23Y/Y Change
Revenue
838.0M
↑ 96.52%
Net Income
100.8M
↓ 124.57%
Net Profit Margin
12.03%
↑ 108.21%
Q4 FY22Q/Q Change
Revenue
112.2M
↑ 0.0%
Net Income
-99.0M
↑ 0.0%
Net Profit Margin
-88.24%
↑ 0.0%
Q1 FY23Q/Q Change
Revenue
266.4M
↑ 137.51%
Net Income
84.3M
↓ 185.14%
Net Profit Margin
31.63%
↑ 119.87%
Q2 FY23Q/Q Change
Revenue
532.9M
↑ 100.0%
Net Income
168.6M
↑ 100.0%
Net Profit Margin
31.63%
↑ 0.0%
Q3 FY23Q/Q Change
Revenue
152.6M
↓ 71.37%
Net Income
-33.9M
↓ 120.1%
Net Profit Margin
-22.21%
↓ 53.84%
Q4 FY23Q/Q Change
Revenue
152.8M
↑ 0.18%
Net Income
12.9M
↓ 138.07%
Net Profit Margin
8.44%
↑ 30.65%
Q2 FY24Q/Q Change
Revenue
305.7M
↑ 100.0%
Net Income
25.8M
↑ 100.0%
Net Profit Margin
8.44%
↑ 0.0%
FY18Y/Y Change
Total Assets
532.1M
↓ 11.01%
Total Liabilities
119.9M
↑ 6.11%
FY19Y/Y Change
Total Assets
465.1M
↓ 12.59%
Total Liabilities
152.2M
↑ 26.99%
FY20Y/Y Change
Total Assets
724.1M
↑ 55.68%
Total Liabilities
205.2M
↑ 34.79%
FY21Y/Y Change
Total Assets
1.4B
↑ 89.56%
Total Liabilities
333.1M
↑ 62.38%
FY22Y/Y Change
Total Assets
1.0B
↓ 25.0%
Total Liabilities
392.6M
↑ 17.84%
FY23Y/Y Change
Total Assets
1.3B
↑ 24.32%
Total Liabilities
536.4M
↑ 36.63%
Q4 FY22Q/Q Change
Total Assets
1.0B
↑ 0.0%
Total Liabilities
392.6M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
1.3B
↑ 0.0%
Total Liabilities
497.5M
-
Q3 FY23Q/Q Change
Total Assets
1.3B
↓ 1.37%
Total Liabilities
536.4M
↑ 7.82%
Q4 FY23Q/Q Change
Total Assets
1.3B
↓ 1.48%
Total Liabilities
508.9M
↓ 5.13%
Q2 FY24Q/Q Change
Total Assets
1.3B
↑ 0.0%
Total Liabilities
508.9M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-32.8M
↑ 267.29%
Investing Cash Flow
43.8M
↓ 116.78%
Financing Cash Flow
-8.2M
↓ 103.01%
FY19Y/Y Change
Operating Cash Flow
-80.9M
↑ 146.33%
Investing Cash Flow
119.0M
↑ 172.05%
Financing Cash Flow
-1.5M
↓ 81.86%
FY20Y/Y Change
Operating Cash Flow
-62.1M
↓ 23.29%
Investing Cash Flow
-125.4M
↓ 205.39%
Financing Cash Flow
296.4M
↓ 19954.92%
FY21Y/Y Change
Operating Cash Flow
-204.2M
↑ 229.04%
Investing Cash Flow
-306.3M
↑ 144.19%
Financing Cash Flow
650.0M
↑ 119.28%
FY22Y/Y Change
Operating Cash Flow
-268.6M
↑ 31.52%
Investing Cash Flow
296.6M
↓ 196.82%
Financing Cash Flow
-82.8M
↓ 112.73%
Q4 FY22Q/Q Change
Operating Cash Flow
167.6M
↓ 287.52%
Investing Cash Flow
18.4M
↑ 0.0%
Financing Cash Flow
-766.6M
↑ 18770.68%

Technicals Summary

Sell

Neutral

Buy

Hutchison China Meditech Limited is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Hutchison China Meditech Limited
Hutchison China Meditech Limited
14.79%
18.26%
18.96%
-39.91%
8.01%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-6.9%
-19.76%
-1.8%
9.18%
27.46%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
0.68%
26.52%
22.93%
40.35%
40.35%
Zoetis Inc.
Zoetis Inc.
0.93%
15.27%
8.78%
-2.45%
51.5%
Viatris Inc.
Viatris Inc.
1.42%
-2.72%
18.32%
-14.96%
-30.05%
Catalent, Inc.
Catalent, Inc.
1.17%
7.09%
38.39%
-53.07%
24.81%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Hutchison China Meditech Limited
Hutchison China Meditech Limited
30.0
NA
0.0
-0.31
-0.05
-0.06
NA
0.87
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
33.7
33.7
0.26
4.57
0.16
0.12
NA
24.87
Haleon Plc Spon Ads
Haleon Plc Spon Ads
32.94
32.94
1.49
0.36
0.07
0.04
0.02
1.82
Zoetis Inc.
Zoetis Inc.
37.45
37.45
2.64
5.82
0.49
0.14
0.01
10.94
Viatris Inc.
Viatris Inc.
224.4
NA
0.07
2.68
-0.03
0.03
0.04
16.36
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.89
0.2
-0.25
0.0
NA
19.91
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Hutchison China Meditech Limited
Hutchison China Meditech Limited
Buy
$3.6B
8.01%
30.0
-6.87%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$11.5B
27.46%
33.7
16.0%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$48.2B
40.35%
32.94
9.66%
Zoetis Inc.
Zoetis Inc.
Buy
$87.2B
51.5%
37.45
26.29%
Viatris Inc.
Viatris Inc.
Hold
$13.6B
-30.05%
224.4
-4.24%
Catalent, Inc.
Catalent, Inc.
Hold
$11.0B
24.81%
211.02
-23.81%

Insights on Hutchison China Meditech Limited

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 152.56M → 305.68M (in $), with an average increase of 25.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -33.88M → 25.80M (in $), with an average increase of 206.3% per quarter

  • Vs CTLT

    In the last 1 year, Catalent, Inc. has given 38.4% return, outperforming this stock by 19.4%

Institutional Holdings

  • Schroder Investment Management Group

    1.77%

  • Allianz Asset Management AG

    0.88%

  • Bellevue Group AG

    0.67%

  • Millennium Management LLC

    0.21%

  • State Street Corp

    0.20%

  • AIA Group Ltd

    0.18%

Company Information

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs.

Organization
Hutchison China Meditech Limited
Employees
1970
CEO
Dr. Wei-Guo Su B.Sc., Ph.D.
Industry
Health Technology

Discover More

FAQs